Romatizmal hastalığı olan bireylerde COVID-19 klinik özelliklerinin ve sonuçlarının değerlendirilmesi

Year 2022, Volume: 47 Issue: 4, 1431 - 1439, 28.12.2022

Gizem Cengiz Senem Şaş

https://doi.org/10.17826/cumj.1097052

Abstract

Amaç: Bu çalışmanın amacı romatizmal hastalığı olan bireylerde koronavirüs hastalığı 2019'un (COVID-19) klinik özelliklerini ve seyrini değerlendirmektir.
Gereç ve Yöntem: Bu retrospektif çalışma, 1 Temmuz-1 Ağustos 2021 tarihleri arasında Erciyes Üniversitesi Romatoloji polikliniğinde gerçekleştirildi. Hastaların demografik ve klinik verileri ile kısa COVID-19 öyküsü ve COVID-19'un klinik seyri, yorgunluk ve ağrı düzeyleri değerlendirildi. Romatizmal hastalığı olan ve COVID-19 geçirmiş olan hastaların verileri kurumsal elektronik kayıt veri tabanımızdan ve hasta dosyalarından elde edilmiştir.
Bulgular: Çalışmaya alınan katılımcılar arasında romatizmal hastalığı olan, laboratuvar testleri ile COVID-19 olduğu doğrulanan ve COVID-19 enfeksiyonundan iyileşmiş olan 106 kişi (%83 kadın, %17 erkek) yer aldı. Yaş ortalamaları 48,69±11,5 yıl ve vücut kitle indeksi (VKİ) 29,89±6,76 kg/m2 idi. Ayrıca 21'i (%19,8) hastaneye kaldırılmış ve beşi (%4,7) yoğun bakıma yatırılmıştı. En sık görülen romatizmal hastalıklar aksiyel spondiloartrit (40; %37.7) ve romatoid artrit (26 vaka; %24.5) idi. Konvansiyonel sentetik hastalık modifiye edici ilaçlar (csDMARD'lar) alan hastalar biyolojik ajan ve nonsteroidal antiinflamatuar ilaç (NSAID) gruplarına göre daha fazla ağrı, yorgunluk ve baş ağrısı yaşadıklarını bildirdi.
Sonuç: Çalışma sonuçlarımız, COVID-19'dan iyileşen ve csDMARD, biyolojik ajan veya NSAID alan romatizmal hastalığı olan hastalar arasında benzer semptomlar ve hastaneye yatış oranlarını ortaya koymaktadır. Ancak csDMARD grubundaki hastalar diğer gruplara göre daha fazla ağrı, yorgunluk ve baş ağrısı bildirdiler.

Keywords

Coronavirüs, COVID-19, romatizmal hastalık, otoimmün

Supporting Institution

yoktur

Project Number

yoktur

Evaluation of COVID-19 clinical features and outcomes in individuals with rheumatic disease

Abstract

features and course of coronavirus disease 2019 (COVID-19) in individuals with rheumatic disease.
Materials and Methods: This retrospective study was carried out at the Erciyes University rheumatology outpatient clinic from July 1 to August 1, 2021. The demographic and clinical data and summarized COVID-19 history, clinical course of COVID-19, fatigue, and pain levels of patients with rheumatic disease were obtained from our institutional electronic registration database and patient files.
Results: Recruited participants were 106 individuals (83% female, %17 male) with rheumatic disease who had been confirmed by laboratory tests to have COVID-19 and recovered from the COVID-19 infection. Their mean age and body mass index (BMI) were 48.69±11.5 years and 29.89±6.76 kg/m2, respectively. Additionally, 21 (19.8%) had been hospitalized, and five (4.7%) had been admitted to the intensive care unit. The most common rheumatic diseases were axial spondyloarthritis (40; 37.7%) and rheumatoid arthritis (26 cases; 24.5%). Patients who received conventional synthetic disease-modifying drugs (csDMARDs) reportedly experienced more pain, fatigue, and headaches than those in the biologic agent and non-steroidal anti-inflammatory drug (NSAID) groups.
Conclusion: Our study results reveal similar symptoms and hospitalization rates among patients with rheumatic disease who recovered from COVID-19 and received either csDMARDs, biologic agents, or NSAIDs. However, patients in the csDMARD group reported more pain, fatigue, and headache compared to the other groups.

Keywords

Coronavirus, rheumatic disease, autoimmune., Coronavirüs, COVID-19, romatizmal hastalık, otoimmün

Project Number

yoktur

References

• 1. Alzahrani ZA, Alghamdi KA. Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. 2021;41(6):1097-103.
• 2. Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, et al. Infections and treatment of patients with rheumatic diseases. Clinical and experimental rheumatology. 2008;26(1 Suppl 48):S67-73.
• 3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033-4.
• 4. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. 2020;369:m1849.
• 5. Pascarella G, Strumia A. COVID-19 diagnosis and management: a comprehensive review. 2020;288(2):192-206.
• 6. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? Journal of medical virology. 2020;92(7):719-25.
• 7. Baj J, Karakuła-Juchnowicz H, Teresiński G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. J Clin Med. 2020;9(6):1753.
• 8. Leiva Sisnieguez CE, Espeche WG, Salazar MR. Arterial hypertension and the risk of severity and mortality of COVID-19. The European respiratory journal. 2020;55(6).
• 9. Chen M, Wei Y, Zhang Q, Wan Q, Chen X. Epidemiology and clinical characteristics of COVID-19 in rheumatic diseases at a tertiary care hospital in Wuhan, China. Clinical and experimental rheumatology. 2021;39(2):442-3.
• 10. Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis Rheumatol. 2020;72(12):1981-9.
• 11. Alzahrani ZA, Alghamdi KA, Almaqati AS. Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. Rheumatology international. 2021;41(6):1097-103.
• 12. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. The American journal of pathology. 2008;173(3):600-9.
• 13. Hasseli R, Mueller-Ladner U, Schmeiser T, Hoyer BF, Krause A, Lorenz HM, et al. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. 2020;6(2).
• 14. Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, Cecchetti R, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clinical rheumatology. 2020;39(11):3195-204.
• 15. D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. 2020;79(9):1156-62.
• 16. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. 2020;79(7):859-66.
• 17. Santos CS, Morales CM, Álvarez ED, Castro C, Robles AL, Sandoval TP. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clinical rheumatology. 2020;39(9):2789-96.
• 18. Galarza-Delgado D, Serna-Peña G, Compeán-Villegas JE, Cardenas-de la Garza JA, Pineda-Sic RA, Colunga-Pedraza IJ, et al. Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy. Clinical rheumatology. 2021;40(3):1197-9. 19. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. The European respiratory journal. 2020;55(5).
• 20. Fernández-de-Las-Peñas C, Gómez-Mayordomo V. The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: A case-control study. 2021;41(13):1332-41.
• 21. Trigo J, García-Azorín D, Sierra-Mencía Á, Tamayo-Velasco Á, Martínez-Paz P. Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients. 2021;22(1):51.
• 22. Tuzun S, Keles A, Okutan D, Yildiran T, Palamar D. Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. European journal of physical and rehabilitation medicine. 2021;57(4):653-62.
• 23. Murat S, Dogruoz Karatekin B. Clinical presentations of pain in patients with COVID-19 infection. 2021;190(3):913-7.
• 24. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data. Front Med (Lausanne). 2021;8:653516-.
• 25. Vehar S, Boushra M, Ntiamoah P, Biehl M. Post-acute sequelae of SARS-CoV-2 infection: Caring for the 'long-haulers'. Cleveland Clinic journal of medicine. 2021;88(5):267-72.